Breast cancer patients who skipped radiation had larger hormone-drug gaps
In a US insurance-claims analysis presented for the Boston oncology meeting, patients who omitted radiation after breast-conserving surgery were more likely to have major gaps in endocrine prescriptions. Only about 28% continuously met the standard pharmacy-availability threshold over five years. The association does not show that radiation improved adherence; the database also excludes patients older than 64, a group often considered for omission.
Science··Morning
Prescription gaps widened over five years
A US insurance-claims analysis announced for the Boston radiation oncology meeting followed people who had breast-conserving surgery for early-stage, hormone receptor-positive cancer. Every person in the group had filled at least one prescription for endocrine therapy, which reduces the hormonal support that can help this cancer grow. Yet only about 28 percent met the usual pharmacy-availability threshold continuously across five years. Looking at each year separately gave much higher proportions, from 59% to 75%. The longer view exposed gaps that a single-year figure could hide.[1]
Radiation omission coincided with larger gaps
People who did not receive radiation after surgery had a roughly twofold higher likelihood of having medicine available for less than half the period. The difference at the conventional 80 percent threshold, however, was not statistically significant. Radiation is used to reduce recurrence in the treated breast, while endocrine medicines form a separate, longer course of care. In selected lower-risk patients, doctors may discuss omitting radiation with an expectation that the medicine will continue. The claims analysis raises a practical question for that plan without showing that radiation itself makes people fill prescriptions more consistently.[1]
Pharmacy claims leave actual dosing unknown
The analysis measures prescriptions filled, not tablets swallowed. Differences in access to care, treatment choices or contact with oncology teams could also separate the groups. Its insurance database covers adults aged 23 to 64, leaving out many older patients for whom omitting radiation is considered. The results are a meeting presentation, not yet a journal article. Within this insured population, the association cannot identify why medicines were missed or establish what would happen to an older patient weighing the two parts of treatment.[1]
